Plain-English translation of NCT06004115 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This study is testing how a single dose of affects how your brain processes fear and worry. Researchers want to understand the differences in how brains with depression, anxiety, or both respond to threatening situations—and whether this medication can help reveal those differences during brain imaging scans.
Depression and anxiety often occur together, but scientists don't fully understand why people with these conditions perceive threats so differently. By studying how this medication affects threat processing in the brain, researchers hope to find new targets for better treatments.
You likely qualify if…
You likely don't qualify if…
You will attend one screening visit (about 2.5 hours) and then two identical experimental sessions (about 5 hours each). During each session, you'll receive either the medication or placebo (you won't know which), and then complete brain imaging and mild electrical stimulation tasks while researchers measure your physical responses. The total time commitment is approximately 10.5 hours spread across three visits.
AI-generated summary from trial data · Jun 26, 2026 · Not medical advice
United States